Physician profile
Marc Lance Strickler
NPI 1215927397
$2,497.54
in general payments reported to CMS, 2019-2025
27 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $91.18 · 2021: $19.19 · 2022: $119 · 2023: $637 · 2024: $607 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.74 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Ipsen Biopharmaceuticals, INC | $372.59 | 2019-2025 | Dysport |
| Merz Pharmaceuticals, LLC | $311.13 | 2022-2025 | Xeomin |
| Allergan, INC. | $123.36 | 2019-2021 | |
| Medtronic, INC. | $87.84 | 2023-2025 | Synchromedii |
| Piramal Critical Care | $74.13 | 2024-2025 | |
| Saol Therapeutics INC. | $70.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $64.09 | 2019-2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $62.11 | 2023 | Nuedexta, Rexulti |
| Amgen INC. | $58.65 | 2019 | |
| Tersera Therapeutics LLC | $57.41 | 2019-2024 | Prialt |
| Scilex Pharmaceuticals INC. | $56.93 | 2019 | |
| Pacira Therapeutics, INC. | $52.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $52.82 | 2023-2024 | Xarelto |
| Merz North America, INC. | $45.88 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $37.63 | 2019 | |
| Trice Medical, INC. | $37.31 | 2024 | |
| Revance Therapeutics, INC. | $25.43 | 2024 | Daxxify |
| Collegium Pharmaceutical, INC. | $16.69 | 2019 | |
| Biodelivery Sciences International, INC. | $16.19 | 2019 | |
| Fidia Pharma USA INC. | $16.04 | 2019 | |
| Bioventus LLC | $15.81 | 2020 | |
| Ibsa Pharma INC. | $13.65 | 2023 | Tirosint, Licart |
| Ermi LLC | $13.35 | 2019 | |
| Depuy Synthes Sales INC. | $12.88 | 2019 | |
| Pfizer INC. | $11.44 | 2019 | |
| Lilly USA, LLC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Strickler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.